Fig. 5
Validation of the advantages of the novel analytical model in the validation cohort. a, b Survival analysis of 65 patients stratified according to the novel analytical model for CpGs 75–78 (a), average method for CpGs 75–78 (a), and Methylation-specific PCR detection results (b). c Predictive accuracies of the novel and average methods, and Methylation-specific PCR testing (d) were evaluated by the receiver operating characteristic curve analysis. AUC area under the curve. e Survival and pathological characteristics of the patients with discrepant results between the novel and average analytical methods. HR, hazard ratio
